valnivudine

Valnivudine (FV-100) is an **orally active nucleoside analogue** developed as a **fast-acting, once-daily antiviral therapy** for herpes zoster (shingles) and associated complications including post-herpetic neuralgia. As a **prodrug of CF-1743**, valnivudine is a **bicyclic nucleoside analogue (BCNA)** that demonstrates **potent and selective inhibition** of varicella zoster virus (VZV) replication.\n\nThe compound has shown substantially **faster and more potent VZV inhibition** compared to currently approved antivirals including aciclovir, famciclovir, and valaciclovir. Upon oral administration, valnivudine is **rapidly and extensively converted** to its active form CF-1743 in the body. The drug exhibits **very low toxicity** in preclinical evaluations.\n\nValnivudine was originally developed through collaboration between **Cardiff University, FermaVir Pharmaceuticals, and Rega Institute for Medical Research**. Development was later advanced by **ContraVir Pharmaceuticals**, which was subsequently renamed **Hepion Pharmaceuticals** in July 2019.

Other names

Valnivudine hydrochlorideFV-100 free baseFV100 free baseFV 100 free base